Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring (PREMEDI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03337802
Recruitment Status : Completed
First Posted : November 9, 2017
Last Update Posted : June 8, 2022
Sponsor:
Information provided by (Responsible Party):
Roberto Berni Canani, MD, PhD, Federico II University

Brief Summary:
The first 1,000 days of life, from the conception to 24 months, are crucial to achieve long-term health outcomes and represent a strategic period to intervene under prevention and public health perspective. Nutritional exposures during this critical period of life can influence the future disease susceptibility. Maternal diet during pregnancy has been linked to offspring overweight/obesity risk and it could represent a potential target for overweight/obesity prevention. The Mediterranean Diet (MD) is considered one of the healthiest dietary models, which impacts beneficially the gut microbiome (GM), providing high amounts of fiber, antioxidants polyphenols and vitamins, and a balanced ratio of essential fatty acids (ω6:ω3). Notably, the MD beneficial effects are due to the synergistic and interactive combinations of nutrients, and the modulation of gene expression through epigenetic changes. Unofrtunately, the MD mechanisms during pregnancy in the prevention of childhood overweight/obesity are not yet fully known.

Condition or disease Intervention/treatment Phase
Food Allergy Behavioral: mediterranean diet Not Applicable

Detailed Description:
The PREMEDI study has been designed to evaluate the effects of Mediterranean Diet during pregnancy on the occurrence of overweight/obesity at 24 months in the offspring.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity at 24 Months in the Offspring
Actual Study Start Date : November 30, 2017
Actual Primary Completion Date : November 30, 2020
Actual Study Completion Date : January 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pregnancy

Arm Intervention/treatment
No Intervention: Pregnant women at standard diet
obstetrical and gynecological follow-up
Experimental: Pregnant women at mediterranean diet
obstetrical and gynecological follow-up + nutritional counseling
Behavioral: mediterranean diet
The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.




Primary Outcome Measures :
  1. The effects of Mediterranean Diet in pregnancy on the occurrence of overweight/obesity at 24 months in the offspring [ Time Frame: After 24 months from the delivery ]
    The children body growth indices are evaluated at 24 months


Secondary Outcome Measures :
  1. The effect of Mediterranean Diet pregnancy on the composition of maternal gut microbiota through analysis of gut microbiota composition. [ Time Frame: after 9 months (at the end of the pregnancy) ]
    Fecal bacteria DNA will be extracted using standard technique outlined by the Earth Microbiome Project. 16S V4-region amplicon libraries will be produced using previously described primers and sequenced using the IlluminaMiSeqplatform (150bpx2). Bacterial load will be determined by qPCR using a standard curve derived from a plasmid containing a single copy of the 16S rRNAencoding gene. Sequence data has been deposited in MG RAST under accession numbers 4571868.3-4571924.3 and project number 10023. Paired end reads will be quality trimmed and processed for OTU (operational taxonomic unit) clustering using UPARSE pipeline, set at 0.97% identity cutoff. Taxonomic status will be assigned to the high quality (<1% incorrect bases) candidate OTUs using the "parallel_assign_taxonomy_rdp.py" script of QIIME software. Multiple sequence alignment and phylogenetic reconstruction will be performed using PyNast and FastTree.

  2. The effect of Mediterranean diet in pregnancy on the production of short chain fatty acids (butyrate and propionate) in the intestinal tract. [ Time Frame: after 9 months (at the end of the pregnancy) ]
    Fecal SCFAs concentration Frozen feces weighing 1g will be diluted with saline solution, vortexed, and centrifuged. Supernatants will be filtered and stored at -20°C until analysis. Frozen fecal extracts will be acidified and extracted in duplicate. A quantity of the pooled extract containing acidified butyrate, propionate or acetate will be transferred into a 2ml glass vial and loaded onto an Agilent Technologies 7890 gas chromatograph (GC) system. Detection will be achieved using a flame ionization detector. Peaks will be identified using a mixed external standard and quantified by peak height/internal standard ratio. To examine whether fecal butyrate levels correlates with bacterial diversity (Shannon diversity index) and evenness (Pielou's evenness index) and abundance patterns across multiple groups we will calculate the Spearman correlation using the cor.test function implemented in R (http://www.r-project.org/

  3. The adherence to Mediterranean Diet in the enrolled women [ Time Frame: from 0 to 9 months (at the end of pregnancy) ]
    Women Mediterranean Diet adherence score is evaluated through the "Med Diet Score"

  4. The effect of dietary counseling on dietary habits [ Time Frame: from 0 to 9 months (at the end of pregnancy) ]
    The diet composition in macro- and micronutrients is evaluated

  5. The effect of Mediterranean diet in pregnancy on the maternal weight gain and complications [ Time Frame: from 0 to 9 months (at the end of pregnancy) ]
    To evaluate the effect of Mediterranean diet in pregnancy on the maternal weight gain and complications (gestational hypertension, infections, gestational diabetes, preeclampsia, use of cesarean)

  6. The effect of Mediterranean diet in pregnancy on perinatal and fetal complications [ Time Frame: from 0 to 9 months (at the end of pregnancy) ]
    Perinatal and fetal complications occurrence are evaluated

  7. The effect of Mediterranean Diet in pregnancy on the duration of breastfeeding and the composition of breast milk [ Time Frame: from 0 to 4 months lactation ]
    The effect of Mediterranean Diet in pregnancy on the duration of breastfeeding and the composition of breast milk (short chain fatty acids, bacterial DNA, adipocytokines.

  8. The effect of Mediterranean Diet on the occurrence of allergies and use of antibiotics in the first 2 years of life. [ Time Frame: Every 6 months from offspring birth to 2 years ]
    The occurrence of allergies and the use of antibiotics in the first 2 years of life are evaluated

  9. The effect of Mediterranean Diet on the epigenetic modulation of genes involved in the regulation of immune system and metabolic pathways in the offspring [ Time Frame: At delivery ]
    The evaluation of the effect of Mediterranean Diet during pregnancy on the epigenetic modulation of genes involved in the immune system and metabolic pathways in the offspring through the cord blood epigenome-wide association study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • women
  • caucasian ethnicity
  • aged between 20 and 35 years

Exclusion Criteria:

  • proven presence of infections during pregnancy and at delivery,
  • twin pregnancy,
  • ongoing malignancies,
  • major gastrointestinal tract malformations,
  • immunodeficiencies,
  • diabetes and other chronic diseases at each organ or apparatus level,
  • chronic intestinal inflammatory diseases,
  • gastrointestinal function disorders,
  • celiac disease;
  • history of abdominal surgery with intestinal resection,
  • neuropsychiatric disorders,
  • central nervous system disorders,
  • vegan diet.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03337802


Locations
Layout table for location information
Italy
University of Naples Federico II
Naples, Italy, 80131
Sponsors and Collaborators
Federico II University
Investigators
Layout table for investigator information
Principal Investigator: Roberto Berni Canani Department of Traslational Medical Science, University of Naples Federico II
Layout table for additonal information
Responsible Party: Roberto Berni Canani, MD, PhD, MD, PhD, Federico II University
ClinicalTrials.gov Identifier: NCT03337802    
Other Study ID Numbers: 298/16
First Posted: November 9, 2017    Key Record Dates
Last Update Posted: June 8, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Overweight
Food Hypersensitivity
Overnutrition
Nutrition Disorders
Body Weight
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases